Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy
European Journal of Neurology · 2024
DOI: 10.1111/ene.16205 ↗At a glance
Journal article in European Journal of Neurology, 2024. Written by Anna Lena Fisse and 14 co-authors. Institution: Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany. Major MEDLINE topics: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Receptors, Fc, Histocompatibility Antigens Class I. Cited 6 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background and purpose Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease with humoral and cellular autoimmunity causing demyelination of peripheral nerves, commonly treated with intravenous immunoglobulins (IVIg). The neonatal Fc receptor (FcRn), encoded by the FCGRT gene, prevents the degradation of immunoglobulin G (IgG) by recycling circulating IgG. A variable number of tandem repeat (VNTR) polymorphism in the promoter region of the FCGRT gene is associated with different expression levels of mRNA and protein. Thus, patients with genotypes associated with relatively low FcRn expression may show a poorer treatment response to IVIg due to increased IVIg degradation.
Methods
VNTR genotypes were analyzed in 144 patients with CIDP. Patients' clinical data, including neurological scores and treatment data, were collected as part of the Immune‐Mediated Neuropathies Biobank registry.
Results
Most patients ( n = 124, 86%) were VNTR 3/3 homozygotes, and 20 patients (14%) were VNTR 2/3 heterozygotes. Both VNTR 3/3 and VNTR 2/3 genotype groups showed no difference in clinical disability and immunoglobulin dosage. However, patients with a VNTR 2 allele were more likely to receive subcutaneous immunoglobulins (SCIg) than patients homozygous for the VNTR 3 allele (25% vs. 9.7%, p = 0.02) and were more likely to receive second‐line therapy (75% vs. 54%, p = 0.05).
Conclusions
The VNTR 2/3 genotype is associated with the administration of SCIg, possibly reflecting a greater benefit from SCIg due to more constant immunoglobulin levels without lower IVIg levels between the treatment circles. Also, the greater need for second‐line treatment in VNTR 2/3 patients could be an indirect sign of a lower response to immunoglobulins.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
- Immune-Mediated Neuropathies Biobank, Ruhr University Bochum, Bochum, Germany.
- Department of Human Genetics, Ruhr University Bochum, Bochum, Germany.
ORCID profiles: Anna Lena Fisse, Rafael Klimas, Thomas Grüter, Jeremias Motte
Cite
APA
Fisse, A. L., Schäfer, E., Hieke, A., Schröder, M., Klimas, R., Brünger, J., Huckemann, S., Grüter, T., Sgodzai, M., Schneider-Gold, C., Gold, R., Nguyen, H. P., Pitarokoili, K., Motte, J., & Arning, L. (2024). Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology. https://doi.org/10.1111/ene.16205
Vancouver
Fisse AL, Schäfer E, Hieke A, Schröder M, Klimas R, Brünger J, et al. Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology. 2024. doi:10.1111/ene.16205
BibTeX
@article{Fisse2024,
author = {Fisse, Anna Lena and Schäfer, Emelie and Hieke, Alina and Schröder, Maximilian and Klimas, Rafael and Brünger, Jil and Huckemann, Sophie and Grüter, Thomas and Sgodzai, Melissa and Schneider-Gold, Christiane and Gold, Ralf and Nguyen, Huu Phuc and Pitarokoili, Kalliopi and Motte, Jeremias and Arning, Larissa},
title = {Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16205}
}
EUVIMED